Solasia Pharma KK (JP:4597)
:4597
Want to see JP:4597 full AI Analyst Report?
4597 Stock Chart & Stats
¥27.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥27.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥27.00 - ¥48.00
Previous CloseN/A
Volume8.51M
Average Volume (3M)41.98M
Market Cap
¥9.28B
Enterprise Value¥9.97B
Total Cash (Recent Filing)¥1.39B
Total Debt (Recent Filing)¥159.00M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA clear 2025 revenue rebound demonstrates improving commercial traction after prior volatility. Sustained top-line growth over several quarters can drive operating leverage, support continued product investment in oncology and supportive care, and reduce near-term reliance on external financing.
Conservative Balance SheetLow leverage and a solid equity base give financial flexibility to fund R&D, absorb ongoing losses, and execute strategic partnerships without immediate refinancing pressure. A conservative balance sheet materially reduces short-term solvency risk during development cycles.
Diversified Partnering-Based ModelA dual revenue model—direct commercialization plus collaboration income—diversifies cash sources and shares development risk. Partner milestones and royalties can provide non-dilutive inflection points and accelerate market access, strengthening medium-term revenue visibility if executed.
Bears Say
Persistent UnprofitabilityDespite revenue gains, entrenched operating and net losses indicate the cost base remains well above revenue. Persistent unprofitability erodes equity, constrains reinvestment, and forces management to prioritize cash preservation or external capital, which can alter strategy and dilute shareholders.
Consistent Cash BurnNegative operating and free cash flows across multiple years demonstrate ongoing cash burn. Even with improvement in 2025, continued negative FCF necessitates external financing, milestone-dependent inflows, or cost cuts—each posing dilution, execution risk, or constrained growth capacity over the medium term.
Margin CompressionA notable decline in gross margin points to mix shifts, pricing pressure, or higher direct costs. Margin deterioration makes scaling to profitability harder, requiring either higher revenue growth or structural cost reductions to achieve sustainable profits and improve cash generation.
Solasia Pharma KK News
4597 FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was ¥27.00 and its highest was ¥48.00 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is ¥9.28B.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is May 20, 2026 which is in 29 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on Feb 13, 2026. The company reported -¥0.53 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.53.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -¥0.53 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in JP:4597
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―
Options Prices
Currently, No data available
---